Results 261 to 270 of about 205,631 (301)

Increased Prostate-Specific Membrane Antigen Uptake in Neurofibromatosis

Clinical Nuclear Medicine, 2020
Abstract A 51-year-old man with 30-year neurofibromatosis and 2-month elevated prostate-specific antigen and back pain underwent a 68Ga–prostate-specific membrane antigen (PSMA) PET/CT scan for possible prostate cancer. Prostate-specific membrane antigen PET/CT imaging showed no abnormal uptake of the prostate.
Yingwei, Wang, Cheng, Zeng, Huipan, Liu, Yue, Chen, Wei, Zhang   +4 more
openaire   +2 more sources

Prostate-specific Membrane Antigen: Diagnostics.

PET clinics
Since its clinical introduction in May 2011, prostate-specific membrane antigen (PSMA)-PET/computed tomography has quickly gained worldwide recognition as a significant breakthrough in prostate cancer diagnostics. In the meantime, several new PSMA radioligands for PET imaging have been introduced into routine clinical practice.
Ian L, Alberts, Robert, Seifert, Rudolf A, Werner, Steven P, Rowe, Ali, Afshar-Oromieh   +4 more
openaire   +2 more sources

Prostate‐specific membrane antigen expression in melanoma metastases

Journal of Cutaneous Pathology, 2020
AbstractBackgroundProstate‐specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga‐PSMA‐11) for prostate cancer staging. PSMA‐PET/CT (positron emission tomography/computed tomography) performed for prostate cancer has been observed to detect melanoma metastases. The aim of this study was to investigate the
Hayden Snow, Stephen Hazell, Nicholas Francis, Kabir Mohammed, Stephanie O'Neill, Emma Davies, David Mansfield, Christina Messiou, Nabil Hujairi, David Nicol, Kevin Harrington, Myles Smith   +11 more
openaire   +3 more sources

Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals

PET Clinics
Novel prostate-specific membrane antigen (PSMA) ligands labeled with α-emitting radionuclides are sparking a growing interest in prostate cancer treatment. These targeted alpha therapies (TATs) have attractive physical properties that deem them effective in progressive metastatic castrate-resistant prostate cancer (mCRPC).
Honest Ndlovu, Kgomotso M.G. Mokoala, Ismaheel Lawal, Louise Emmett, Mike M. Sathekge   +4 more
openaire   +2 more sources

Radiolabeled prostate-specific membrane antigen small-molecule inhibitors

The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017
Prostate cancer (PC) is one of the most common malignancies worldwide. Prostate-specific membrane antigen (PSMA) has been found to be expressed in most PCs and represents an ideal target for diagnostic and therapeutic purposes. Numerous PSMA tracers have been recently developed.
Leon, Will, Ida, Sonni, Klaus, Kopka, Clemens, Kratochwil, Frederik L, Giesel, Uwe, Haberkorn   +5 more
openaire   +2 more sources

Prostate Specific Membrane Antigen Based Imaging

2021
Positron emission tomography-computed tomography (PET-CT) performed with new radiopharmaceuticals has revolutionized the imaging area in prostate cancer (Pca). 68Ga/18F-labeled prostate-specific membrane antigen (PSMA) has been the most promising radiotracer for staging and restaging of Pca.
openaire   +1 more source

Prostate Specific Membrane Antigen-Based Diagnostics

2012
At present, prostate cancer imaging is performed for lesion localization, detection of recurrent and/or metastatic disease, and staging. Despite significant efforts, conventional imaging of prostate cancer does not contribute to patient management as much as imaging performed for other common cancers.
Joseph R. Osborne, Kofi Deh, Alok Azad Anand, Neil H. Bander, Scott T. Tagawa   +4 more
openaire   +1 more source

Gallium-68 Prostate-Specific Membrane Antigen PET Imaging

PET Clinics, 2017
The role of gallium-68 (68Ga) prostate-specific membrane antigen (PSMA) PET imaging is evolving and finding its place in the imaging armamentarium for prostate cancer (PCa). Despite the progress of conventional imaging strategies, significant limitations remain, including identification of small-volume disease and assessment of bone.
Michael S, Hofman, Amir, Iravani
openaire   +2 more sources

Prostate-Specific Membrane Antigen in Low-Grade Fibromatosis

Clinical Nuclear Medicine, 2017
Abstract We report a case of fibromatosis demonstrating prostate-specific membrane antigen (PSMA)–positive scan. A 76-year-old man was under assessment because of rising prostate-specific antigen level. Bone scan showed abnormal soft tissue uptake of 99mTc-MDP adjacent to the right scapula, compatible with a mass in MRI, thereafter.
Ramin, Akbarian Aghdam, Masoumeh, Hakiminejad, Hamidreza, Hashemifard, Azadeh, Rakhshan, Elahe, Pirayesh   +4 more
openaire   +2 more sources

Cloning and characterization of canine prostate‐specific membrane antigen

The Prostate, 2013
AbstractBACKGROUNDProstate‐specific membrane antigen (PSMA) is a promising biomarker in the diagnosis of prostate cancer and a potential target for antibody‐based therapeutic strategies. We isolated the canine PSMA cDNA and investigated the cellular and biochemical characteristics of the recombinant protein as a potential target for animal preclinical ...
Schmidt S., FRACASSO, Giulio, COLOMBATTI, Marco, Naim H. Y.   +3 more
openaire   +2 more sources